Study guide
3.2 Intravenous Hypnotics: Propofol, Etomidate, Ketamine & Barbiturates
NBCRNA CRNA Certified Registered Nurse Anesthetist NCE
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Cardiovascular, Respiratory & CNS Physiology & Pathophysiology
1.1 Cardiovascular Physiology, Hemodynamics & Ischemic Heart Disease 1.2 Respiratory Physiology, Lung Volumes & Chronic Pulmonary Pathophysiology 1.3 Central & Autonomic Nervous System Physiology & Neurological Disorders
2 Chapter 2: Hepatorenal, Endocrine & Hematologic/Immune Systems
2.1 Renal Physiology, Glomerular Filtration & Acid-Base Balance 2.2 Hepatic Physiology, Drug Clearance & Gastrointestinal Considerations 2.3 Endocrine Disorders, Hematology, Coagulation & Immune Mechanisms
3 Chapter 3: Anesthetic Pharmacology: Inhalation Agents, Intravenous Anesthetics & Sedatives
3.1 Inhalation Anesthetics: Uptake, Distribution, Blood/Gas Solubility & MAC 3.2 Intravenous Hypnotics: Propofol, Etomidate, Ketamine & Barbiturates 3.3 Opioid Agonists/Antagonists, Benzodiazepines & Reversal Pharmacology
4 Chapter 4: Anesthetic Pharmacology: Neuromuscular Blockers, Local Anesthetics & Physics
4.1 Neuromuscular Blocking Agents & Reversal: Anticholinesterases vs Sugammadex 4.2 Local Anesthetics: Mechanism, Potency, Toxicity (LAST) & Vasoconstrictors 4.3 Applied Physics, Gas Laws, Fluid Dynamics & Anesthesia Mathematics
5 Chapter 5: Anesthesia Delivery Systems & Gas Supplies
5.1 Medical Gas Supply Systems, Cylinders, Regulators & Safety Index Systems (PISS/DISS) 5.2 Anesthesia Machine High, Intermediate & Low Pressure Systems & Failsafe Mechanisms 5.3 Vaporizer Technology: Variable-Bypass vs Desflurane Vaporizers & Machine Checkout
6 Chapter 6: Breathing Circuits, CO2 Absorption & Ventilators
6.1 Breathing Circuits: Circle System, Mapleson Classifications & Dead Space 6.2 Carbon Dioxide Absorption: Soda Lime Chemistry, Desiccation, Carbon Monoxide & Compound A 6.3 Anesthesia Ventilators, Pressure/Volume Modes, APL Valves & Waste Gas Scavenging
7 Chapter 7: Airway Equipment & Advanced Airway Instrumentation
7.1 Face Masks, Supraglottic Airways (LMA Types) & Endotracheal Tubes 7.2 Direct Laryngoscopy (Mac/Miller) & Video Laryngoscopy 7.3 Fiberoptic Intubation, Bronchial Blockers, Double-Lumen Tubes & Surgical Airways
8 Chapter 8: Patient Monitoring, Hemodynamics & Electrosurgical Safety
8.1 Noninvasive Monitoring: Pulse Oximetry, Capnography Waveforms & Temperature 8.2 Invasive Hemodynamics: Arterial Lines, CVP & Pulmonary Artery Catheters 8.3 Neuromuscular Monitoring (TOF/PTC), Depth of Anesthesia (EEG/BIS) & Electrical Safety
9 Chapter 9: Preoperative Assessment, Risk Stratification & Preparation
9.1 Preoperative History, Physical Examination & ASA Physical Status Classification 9.2 Cardiac & Pulmonary Risk Stratification, Diagnostic Testing & Optimization 9.3 Preoperative Fasting Guidelines, Aspiration Prophylaxis & Premedication
10 Chapter 10: Fluid Management, Blood Component Therapy & Coagulation Monitoring
10.1 Crystalloids vs Colloids, Maintenance & Deficit Calculations 10.2 Blood Component Therapy, Transfusion Triggers & Massive Transfusion Protocols 10.3 Point-of-Care Coagulation: TEG, ROTEM & Perioperative Coagulopathies
11 Chapter 11: Airway Management Strategies & Difficult Airway Algorithms
11.1 Difficult Airway Assessment: Mallampati, Cormack-Lehane & Airway Predictors 11.2 ASA Difficult Airway Algorithm: Anticipated vs Unanticipated Difficult Airway 11.3 "Cannot Intubate, Cannot Oxygenate" (CICO) & Emergency Front-of-Neck Access (eFONA)
12 Chapter 12: General Anesthesia: Induction, Maintenance, Emergence & TIVA
12.1 Rapid Sequence Induction (RSI), Cricoid Pressure & Intubation Protocols 12.2 Balanced Anesthesia vs Total Intravenous Anesthesia (TIVA) Principles 12.3 Emergence, Extubation Criteria, Deep vs Awake Extubation & Laryngospasm
13 Chapter 13: Regional Anesthesia: Neuraxial Blocks
13.1 Spinal Anesthesia: Anatomy, Physiology, High Spinal & Complications 13.2 Epidural & Combined Spinal-Epidural (CSE) Techniques & PDPH 13.3 Neuraxial Anticoagulation Guidelines (ASRA) & Epidural Hematoma
14 Chapter 14: Regional Anesthesia: Peripheral Nerve Blocks & Ultrasound Guidance
14.1 Upper Extremity Peripheral Nerve Blocks: Interscalene, Supraclavicular, Axillary 14.2 Lower Extremity & Truncal Blocks: Femoral, Sciatic, TAP & ESP Blocks 14.3 Ultrasound Physics, Needle Visualization & LAST Rescue Protocols
15 Chapter 15: Perioperative Safety, Positioning, PACU, Ethics & Professional Practice
15.1 Surgical Positioning Complications: Nerve Injuries & Physiologic Changes 15.2 PACU Discharge Criteria, PONV Management, Hypoxemia & Emergence Delirium 15.3 Malignant Hyperthermia Protocol & Operating Room Crisis Management 15.4 CRNA Ethics, Informed Consent, Scope of Practice & Wellness Initiatives
16 Chapter 16: Obstetric & Gynecologic Anesthesia
16.1 Maternal Physiology & Pharmacokinetics Across Trimesters 16.2 Labor Analgesia & Anesthesia for Cesarean Delivery 16.3 Obstetric Emergencies: Preeclampsia, Hemorrhage & Amniotic Fluid Embolism 16.4 Nonobstetric Surgery in the Pregnant Patient
17 Chapter 17: Pediatric Anesthesia
17.1 Pediatric Anatomy, Physiology, Airway & Developmental Pharmacology 17.2 Pediatric Induction, Maintenance, Fluids & Emergence Agitation 17.3 Pediatric Respiratory Emergencies: Croup, Epiglottitis & Laryngospasm
18 Chapter 18: Geriatric, Bariatric & Ambulatory Anesthesia
18.1 Geriatric Physiology, Pharmacodynamics & Postoperative Delirium/POCD 18.2 Bariatric Anesthesia: Obesity Hypoventilation, OSA & Dosing Adjustments 18.3 Ambulatory Surgery Selection Criteria & ERAS Protocols
19 Chapter 19: Cardiac, Vascular & Thoracic Anesthesia
19.1 Valvular Heart Disease, CAD & Cardiopulmonary Bypass Management 19.2 Vascular Anesthesia: Carotid Endarterectomy & Aortic Cross-Clamping 19.3 Thoracic Anesthesia: One-Lung Ventilation & Hypoxic Pulmonary Vasoconstriction
20 Chapter 20: Neurosurgical, Intra-Abdominal, Extrathoracic, Head/Neck & Trauma Anesthesia
20.1 Neurosurgical Anesthesia: ICP Dynamics, Craniotomy & Venous Air Embolism 20.2 Intra-Abdominal, Laparoscopy & Endocrine Tumor Anesthesia (Pheochromocytoma, Carcinoid) 20.3 ENT/Shared Airway, Extrathoracic Procedures & Trauma/Burn Resuscitation
21 Chapter 21: Neurologic, Gastrointestinal & Substance-Related Pathophysiology and Pharmacology
21.1 Neurodegenerative & Demyelinating Disease and Antiparkinsonian Pharmacology 21.2 Gastrointestinal & Exocrine Pancreatic Disorders: Esophageal, Gastric, Pancreatitis & Malabsorption 21.3 Cannabinoids, Herbal Remedies & Dietary Supplements
22 Chapter 22: Imaging Safety, Patient Warming & Infusion Technology
22.1 Fluoroscopy, Radiography & Radiation Safety in Anesthetizing Locations 22.2 Patient Warming Equipment & Rapid Infusion Devices
23 Chapter 23: Pain Medicine: Theory, Chronic Pain & Interventional Procedures
23.1 Pain Theory: Nociception, Sensitization & Chronic Pain Pathophysiology 23.2 Chronic Pain Management, Medication-Assisted Therapy & the Opioid-Tolerant Patient 23.3 Interventional Pain Procedures & Anesthesia for Pain Management Cases
24 Chapter 24: Professional Practice: Research Ethics, Error Disclosure & Provider Infection Control
24.1 Research Ethics, IRB Oversight & Protection of Human Subjects 24.2 Disclosure of Errors and Injuries, Adverse Event Reporting & Just Culture 24.3 Provider Infection Control: PPE, Air Handling & Occupational Exposure
25 Chapter 25: Neurosurgical Subspecialty Procedures
25.1 Cerebral Aneurysm Clipping, AVM Resection & Subarachnoid Hemorrhage 25.2 Transsphenoidal Hypophysectomy & Pituitary Surgery 25.3 Stereotactic Procedures, Deep Brain Stimulation & Awake Craniotomy 25.4 CSF Diversion, Burr Holes, Ventriculoperitoneal Shunts & Decompressive Craniectomy
26 Chapter 26: Head, Neck, Nasal, Dental & Ophthalmic Anesthesia
26.1 Nasal & Sinus Surgery, Nasotracheal Intubation & Craniofacial Procedures 26.2 Dental, Orthodontic, Oral-Maxillofacial & Ophthalmic Anesthesia 26.3 Neck Tumors, Radical Neck Dissection, Lymph Node Biopsy & Thyroid/Parathyroid Surgery
27 Chapter 27: Orthopedic & Extremity Anesthesia
27.1 Total Joint Arthroplasty, Bone Cement Implantation Syndrome & Tourniquet Physiology 27.2 Closed Reduction, Hand and Foot Procedures & Intravenous Regional (Bier) Block
28 Chapter 28: Non-Operating-Room Anesthesia: Interventional, Imaging & Radiation Therapy
28.1 Interventional and Neurointerventional Radiology Anesthesia 28.2 Radiation Therapy, Diagnostic Imaging & MRI-Suite Anesthesia
29 Chapter 29: Special Populations: Substance Use Disorder, Immunocompromised & Oncology Patients
29.1 Acute Intoxication, Withdrawal Syndromes & Perioperative Complications 29.2 Anesthesia for the Immunocompromised & Oncology Patient
3.2 Intravenous Hypnotics: Propofol, Etomidate, Ketamine & Barbiturates
Key Takeaways Explain This Topic AI
Propofol enhances GABA-A receptor activity by increasing chloride channel open duration; its termination of action after a single bolus is driven by redistribution from the central vessel-rich compartment to muscle and fat, while its context-sensitive half-time remains <40 minutes even after infusions lasting up to 8 hours.
Propofol Infusion Syndrome (PRIS) is a life-threatening mitochondrial toxidrome resulting from prolonged (>48h), high-dose (>4-5 mg/kg/h) infusions, characterized by refractory lactic acidosis, rhabdomyolysis, hypertriglyceridemia, hepatomegaly, renal failure, and Brugada-like ECG patterns with cardiovascular collapse.
Etomidate provides unmatched cardiovascular stability by maintaining sympathetic tone and baroreceptor sensitivity, but causes reversible, dose-dependent inhibition of 11β-hydroxylase, suppressing adrenocortical cortisol synthesis for 6 to 24 hours.
Ketamine is a non-competitive NMDA receptor antagonist producing a dissociative state, indirect sympathomimetic stimulation (increased BP, HR, CO), and potent bronchodilation; it acts as a direct myocardial depressant when endogenous catecholamine stores are fully depleted.
Methohexital (0.75-1.0 mg/kg) is the agent of choice for Electroconvulsive Therapy (ECT) due to its ability to lower seizure threshold and optimize therapeutic seizure duration, whereas barbiturates are strictly contraindicated in acute intermittent porphyria.
Last updated: August 2026
3.2 Intravenous Hypnotics: Propofol, Etomidate, Ketamine & Barbiturates
Intravenous induction hypnotics are the primary agents used to achieve rapid loss of consciousness for general anesthesia, procedural sedation, and total intravenous anesthesia (TIVA). Understanding their distinct receptor pharmacology, multi-compartment pharmacokinetics, hemodynamic profiles, and toxicity profiles is essential for safe anesthesia practice.
1. Pharmacokinetic Principles: Redistribution & Context-Sensitive Half-Time
Intravenous hypnotics distribute according to a three-compartment pharmacokinetic model :
V 1 V_1 V 1 (Central Compartment): Intravascular volume and highly perfused vessel-rich organs (brain, heart, liver, kidneys), representing ~10% of body mass but receiving ~75% of cardiac output.
V 2 V_2 V 2 (Fast Peripheral Compartment): Muscle and skin.
V 3 V_3 V 3 (Slow Peripheral Compartment): Adipose tissue and poorly perfused tissues.
Redistribution vs. Elimination
Following a single IV induction bolus, awakening occurs within 5 to 10 minutes . This termination of effect is NOT due to hepatic metabolism or renal excretion , but rather to rapid redistribution of drug from the vessel-rich central compartment ( V 1 V_1 V 1 ) to the muscle/fat peripheral compartments ( V 2 V_2 V 2 and V 3 V_3 V 3 ), causing central nervous system drug concentrations to fall below the hypnotic threshold.
Context-Sensitive Half-Time (CSHT)
Definition: The time required for the central compartment (plasma) drug concentration to decrease by 50% following the termination of a continuous, steady-state IV infusion of a specified duration (the "context").
Propofol: Exhibits a stable CSHT of <40 minutes even after prolonged continuous infusions lasting up to 8 hours. This occurs because rapid metabolic clearance (hepatic + extrahepatic) continuously clears drug from the central compartment while peripheral tissues slowly release stored drug.
Thiopental & Diazepam: Demonstrate steep increases in CSHT with prolonged infusions because peripheral compartments saturate, and clearance is too slow to prevent high plasma concentrations upon redistribution back into V 1 V_1 V 1 .
Etomidate: Short CSHT (~20–30 minutes) due to rapid ester hydrolysis by hepatic and plasma esterases.
Ketamine: Relatively short CSHT (~30–45 minutes) due to high clearance and large volume of distribution.
- 2. Propofol (2,6-Diisopropylphenol)
- Formulation & Physicochemical Characteristics
Vehicle: Highly lipophilic oil formulated in a 1% aqueous emulsion containing 10% soybean oil, 2.25% glycerol, and 1.2% purified egg phosphatide (egg yolk lecithin).
Allergy Considerations: Egg yolk contains lecithin (phosphatidylcholine), whereas true egg allergies are mediated by ovalbumin in egg whites. True soy allergy is directed against soy proteins, not refined soybean oil. Propofol is generally safe in patients with egg white allergy, but is avoided in cases of documented anaphylaxis to propofol emulsion components.
Preservatives & Microbial Growth: Diprivan brand contains 0.005% disodium edetate (EDTA) ; generic formulations contain 0.025% sodium metabisulfite (can trigger bronchospasm in sulfite-sensitive asthmatics) or benzyl alcohol. Because the lipid emulsion supports rapid microbial growth, vials and prefilled syringes must be used within 6 to 12 hours of opening using strict aseptic technique.
Mechanism of Action
Propofol binds selectively to the β \beta β -subunit ( β 1 , β 2 , β 3 \beta_1, \beta_2, \beta_3 β 1 , β 2 , β 3 ) of the pentameric G A B A A GABA_A G A B A A receptor complex, acting as a positive allosteric modulator to increase the duration of channel opening in response to endogenous GABA. At higher concentrations, propofol directly gates and opens the G A B A A GABA_A G A B A A chloride channel in the absence of GABA, causing neuronal hyperpolarization and profound CNS depression.
Organ System Effects
Central Nervous System:
Decreases Cerebral Metabolic Rate of Oxygen ( ↓ C M R O 2 \downarrow CMRO_2 ↓ CMR O 2 by ~35–45%), Cerebral Blood Flow ( ↓ C B F \downarrow CBF ↓ CBF ), Intracranial Pressure ( ↓ I C P \downarrow ICP ↓ I CP ), and Intraocular Pressure ( ↓ I O P \downarrow IOP ↓ I OP ).
Produces burst suppression on electroencephalogram (EEG) at high doses; possesses potent anticonvulsant properties.
Myoclonic twitches or subcortical excitatory movements may occur upon induction (subcortical disinhibition, not true cortical epileptiform activity).
Cardiovascular System:
Profound systemic hypotension: Caused by direct arterial vasodilation (decreases Systemic Vascular Resistance, ↓ S V R \downarrow SVR ↓ S V R ) and venodilation (decreases preload / venous return).
Direct negative inotropic effect (decreases myocardial intracellular C a 2 + Ca^{2+} C a 2 + availability).
Blunts the arterial baroreceptor reflex: Prevents compensatory reflex tachycardia despite severe hypotension, occasionally resulting in profound bradycardia or asystole (especially when co-administered with opioids, β \beta β -blockers, or in elderly/hypovolemic patients).
Respiratory System:
Dose-dependent respiratory depression; induction doses produce central apnea in 25–35% of patients.
Blunts ventilatory responses to both arterial hypercapnia and hypoxemia.
Suppresses upper airway and pharyngeal reflexes: Superior to all other agents for laryngeal mask airway (LMA) insertion without neuromuscular blockade.
Causes bronchodilation by relaxing airway smooth muscle.
Unique Properties:
Antiemetic: Low-dose boluses (10–20 mg IV) or low-rate infusions (10–20 mcg/kg/min) directly suppress the chemoreceptor trigger zone (CTZ) and reduce postoperative nausea and vomiting (PONV).
Antipruritic: 10 mg IV relieves neuraxial opioid-induced and cholestatic pruritus.
Propofol Infusion Syndrome (PRIS)
PRIS is a catastrophic, often fatal syndrome resulting from impaired cellular mitochondrial fatty acid oxidation and oxidative phosphorylation uncoupling.
Risk Factors: Infusions exceeding 4 to 5 mg/kg/h (67–83 mcg/kg/min) for >48 hours , critical illness, sepsis, severe head trauma, high exogenous catecholamine or corticosteroid administration, and pediatric ICU sedation.
Pathophysiology: Inhibits entry of long-chain fatty acids into mitochondria (inhibits carnitine palmitoyltransferase-1) and blocks electron transport chain complexes I and IV, forcing cells into anaerobic metabolism.
Clinical Manifestations:
- Refractory, severe high-anion-gap lactic acidosis
- Rhabdomyolysis with massive creatine kinase (CK) elevation and myoglobinuria
- Acute renal failure and hyperkalemia
- Hepatomegaly and hypertriglyceridemia (lipemic serum)
Cardiac dysrhythmias: Brugada-like ECG pattern (coved ST-segment elevation in V1–V3), right bundle branch block (RBBB), refractory bradycardia, cardiogenic shock, and asystole.
Management: Immediate cessation of propofol infusion, aggressive supportive care, hemodialysis/CRRT for acid-base correction, and extracorporeal membrane oxygenation (ECMO) if cardiogenic shock ensues.
- 3. Etomidate (Carboxylated Imidazole Derivative)
- Formulation & Dosing
Structure: Carboxylated imidazole containing a chiral center (formulated as the active R R R -(+) enantiomer, which has 12-fold greater hypnotic activity than the S S S -(-) isomer).
Vehicle: Formulated in 35% propylene glycol ( p H ≈ 6.9 pH \approx 6.9 p H ≈ 6.9 ). Propylene glycol causes significant pain on injection, local irritation, thrombophlebitis, and transient hemolysis.
Induction Dose: 0.2 to 0.3 mg/kg IV .
Mechanism of Action
Selective positive allosteric modulator of the G A B A A GABA_A G A B A A receptor , binding specifically to the β 2 \beta_2 β 2 and β 3 \beta_3 β 3 subunits to enhance chloride conductance.
Organ System Effects & Adrenocortical Suppression
Cardiovascular System:
Exceptional hemodynamic stability: Minimal to no change in heart rate, mean arterial pressure, stroke volume, cardiac index, pulmonary artery pressure, or systemic vascular resistance.
Does not blunt autonomic baroreflexes or suppress sympathetic tone; myocardial oxygen supply/demand ratio is preserved.
Agent of choice for induction in patients with severe aortic stenosis, severe coronary artery disease, cardiomyopathy, congestive heart failure, or hypovolemic shock.
Central Nervous System:
Potent cerebral vasoconstrictor: Decreases C M R O 2 CMRO_2 CMR O 2 (~35–45%), ↓ C B F \downarrow CBF ↓ CBF , and ↓ I C P \downarrow ICP ↓ I CP , while maintaining mean arterial pressure, thereby preserving Cerebral Perfusion Pressure ( C P P = M A P − I C P CPP = MAP - ICP CPP = M A P − I CP ).
High incidence of myoclonus (30–60%) : Caused by subcortical disinhibition of extrapyramidal pathways (not seizure activity). Can be attenuated by pretreatment with low-dose opioids (fentanyl 1–2 mcg/kg) or midazolam.
Endocrine Adrenocortical Suppression (Board Essential):
Etomidate causes dose-dependent, reversible inhibition of 11 β 11\beta 11 β -hydroxylase (and to a lesser degree 17 α 17\alpha 17 α -hydroxylase), the mitochondrial cytochrome P450 enzyme responsible for converting 11-deoxycortisol to cortisol and 11-deoxycorticosterone to aldosterone .
A single induction dose (0.3 mg/kg) suppresses cortisol and aldosterone synthesis and blunts the adrenocortical response to adrenocorticotropic hormone (ACTH) stimulation for 6 to 24 hours .
Continuous infusions are strictly contraindicated due to documented increased mortality in critically ill septic and trauma patients.
Gastrointestinal: High incidence of postoperative nausea and vomiting (PONV, up to 30–40%).
- 4. Ketamine (Phencyclidine Derivative)
- Chirality & Formulation
Structure: Arylcyclohexylamine structurally related to phencyclidine (PCP).
Enantiomers: Commercial preparation in the US is a racemic mixture of S − ( + ) S-(+) S − ( + ) and R − ( − ) R-(-) R − ( − ) ketamine. The S − ( + ) S-(+) S − ( + ) enantiomer (esketamine) has 3 to 4 times greater affinity for NMDA receptors, provides twice the analgesic potency, causes less emergence agitation, and exhibits faster hepatic clearance than the R − ( − ) R-(-) R − ( − ) isomer.
Induction Dosing: 1.0 to 2.0 mg/kg IV (or 4.0 to 6.0 mg/kg IM for uncooperative pediatric/trauma patients).
Mechanism of Action & Dissociative Anesthesia
Primary Mechanism: Non-competitive antagonist of the NMDA ( N N N -methyl- D D D -aspartate) receptor , binding open-channel to the phencyclidine ( P C P PCP PCP ) site inside the calcium-permeable cation pore, inhibiting glutamate activation.
Also inhibits HCN1 (hyperpolarization-activated cyclic nucleotide-gated 1) channels , interacts with μ , κ , δ \mu, \kappa, \delta μ , κ , δ opioid receptors, monoaminergic receptors, and muscarinic acetylcholine receptors.
Dissociative Anesthesia: Electrophysiologically dissociates the limbic system (which processes emotion and pain awareness) from the thalamocortical sensory projection systems. The patient appears awake (eyes open with slow nystagmic gaze), has intact corneal and cough reflexes, but is cataleptic, profoundly amnestic, and insensitive to noxious surgical stimulation.
Organ System Effects
Cardiovascular System:
Indirect Sympathomimetic: Stimulates central sympathetic outflow and inhibits neuronal reuptake of norepinephrine, leading to increased heart rate, arterial blood pressure, cardiac output, systemic vascular resistance, and pulmonary vascular resistance (PVR) .
Direct Myocardial Depressant: In patients with end-stage shock or chronic critically ill states where endogenous catecholamine stores are fully depleted , the direct negative inotropic effect of ketamine is unmasked, resulting in paradoxical hypotension and cardiac collapse.
Respiratory System:
Potent Bronchodilator: Relaxes bronchial smooth muscle via sympathetic β 2 \beta_2 β 2 -stimulation and direct vagolytic antagonism; agent of choice for induction in severe acute status asthmaticus .
Preserves spontaneous ventilation and upper airway protective reflexes (though aspiration can still occur).
Increases upper airway secretions and salivation (often co-administered with an anticholinergic like glycopyrrolate 0.2 mg IV ).
Central Nervous System:
Classically increases C M R O 2 CMRO_2 CMR O 2 , C B F CBF CBF , I C P ICP I CP , and I O P IOP I OP via cerebral vasodilation (historically avoided in closed-head injury or elevated ICP, though modern controlled normocapnic ventilation attenuates these increases).
Emergence delirium / psychotomimetic reactions occur in 10–30% of patients (vivid dreams, hallucinations, floating sensations, agitation). Prevention: Pretreatment with Midazolam (1–2 mg IV) or Propofol co-administration.
Loading diagram... Hemodynamic, Cerebral, and Respiratory Comparison of IV Hypnotics
- 5. Barbiturates (Thiopental & Methohexital)
- Mechanism & Chemistry
Chemistry: Derived from barbituric acid. Thiobarbiturates have a sulfur atom at C2 (e.g., Thiopental), increasing lipid solubility and potency; Oxybarbiturates have an oxygen atom at C2 (e.g., Methohexital, Pentobarbital).
Formulation: Dissolved in anhydrous sodium carbonate to maintain an alkaline p H > 10.5 pH > 10.5 p H > 10.5 . When mixed with acidic drugs (such as rocuronium, vecuronium, or opioids), barbiturates immediately precipitate as insoluble free acids , occluding IV cannulas.
Mechanism: Positive allosteric modulation of G A B A A GABA_A G A B A A receptors at low concentrations; direct chloride channel opening and suppression of AMPA glutamate transmission at high concentrations.
Clinical Profiles & Porphyria Contraindication
Methohexital (Brevital, 0.75–1.0 mg/kg IV): Gold standard induction agent for Electroconvulsive Therapy (ECT) . Unlike propofol and thiopental (which shorten seizure duration), methohexital activates cortical epileptogenic foci, lowers the seizure threshold, and produces prolonged, high-quality therapeutic seizures.
Intra-arterial Injection Hazard: Inadvertent intra-arterial injection of thiopental causes severe chemical endarteritis, crystal precipitation, intense vasoconstriction, platelet aggregation, and distal limb gangrene. Treatment: Leave arterial catheter in place; inject heparin, papaverine or procaine (vasodilator), lidocaine, and perform an immediate stellate ganglion block or brachial plexus sympathetic block.
Absolute Contraindication: Acute Intermittent Porphyria, Variegate Porphyria, and Hereditary Coproporphyria . Barbiturates induce the rate-limiting hepatic enzyme δ \delta δ -aminolevulinic acid (ALA) synthetase , accelerating porphyrin accumulation and precipitating life-threatening neurovisceral crises (severe abdominal pain, peripheral neuropathy, paralysis, psychiatric derangements, and autonomic instability).
- 6. Dexmedetomidine (Selective α 2 \alpha_2 α 2 -Adrenergic Agonist)
- Pharmacology & Receptor Selectivity
Structure: Imidazole compound with an α 2 : α 1 \alpha_2:\alpha_1 α 2 : α 1 receptor selectivity ratio of 1620:1 (compared to 220:1 for clonidine).
Mechanism: Stimulates pre- and postsynaptic α 2 \alpha_2 α 2 -adrenergic receptors. Sedative and hypnotic actions are mediated specifically by stimulating presynaptic α 2 A \alpha_2A α 2 A receptors in the locus coeruleus of the brainstem, decreasing adenylyl cyclase activity, inhibiting central norepinephrine outflow, and disinhibiting the ventrolateral preoptic nucleus (VLPO).
"Cooperative / Biomimetic Sedation": Induces a state resembling non-REM Stage 3 (N3) slow-wave sleep. Patients are easily arousable to verbal stimuli, cooperative with neurological assessments, and follow commands, then readily drift back to sleep when left undisturbed.
Clinical Effects & Hemodynamic Profile
Respiratory: Zero to minimal respiratory depression ; preserves ventilatory response to hypercapnia and preserves airway patency (ideal for awake fiberoptic intubation and weaning mechanical ventilation in the ICU).
Analgesic-Sparing: Reduces intraoperative opioid requirements by 30–50% and provides potent anti-shivering effects ( 0.5 μ g/kg 0.5\ \mu\text{g/kg} 0.5 μ g/kg IV).
Biphasic Hemodynamic Response: Rapid IV bolus administration activates peripheral vascular α 2 B \alpha_2B α 2 B receptors on vascular smooth muscle, causing transient vasoconstriction and hypertension with reflex bradycardia. This is followed by sustained central α 2 A \alpha_2A α 2 A -mediated sympatholysis, resulting in systemic hypotension and bradycardia .
Dosing: Loading infusion of 0.5 to 1.0 mcg/kg over 10 minutes , followed by maintenance infusion of 0.2 to 0.7 mcg/kg/h .